info icon

Nanophthalmos, microphthalmos and macrophthalmos

Q17_ANOPH_MICROPHT_MACROP

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 Q11
  • Cause of death: ICD-10 Q11

2 out of 7 registries used, show all original rules.

19

4. Check minimum number of events

None

19

5. Include endpoints

None

19

6. Filter based on genotype QC (FinnGen only)

19

Control definitions (FinnGen only)

Control exclude
Q17_CONGEN_MALFO_EYE_EAR_FACE_NECK

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q1
Name in latin
Anophthalmia, microphthalmia sive macrophthalmia

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 360 175 184
Only index persons 297 144 153
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 18.81 15.32 21.80
Only index persons 25.43 21.83 28.82

-FinnGen-

Key figures

All Female Male
Number of individuals 19 11 8
Unadjusted period prevalence (%) 0.00 0.00 0.00
Median age at first event (years) 48.25 35.13 66.29

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

No data available

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3007853) Bacteria identified in Skin by Aerobe culture
9
27
5.37
2.88
3.1
1.3
—
—
—
0
0
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
6
12
6.73
2.63
6.0
3.2
%
76.7
39.7
—
6
12
(3004119) Hemoglobin [Mass/volume] in Venous blood
6
12
6.73
2.63
3.5
19.1
g/l
135.3
126.9
—
6
12
(3027273) Bicarbonate [Moles/volume] in Venous blood
6
12
6.73
2.63
5.3
2.8
mmol/l
24.9
23.5
—
6
12
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
5
10
6.33
2.22
1.0
2.3
—
—
—
0
0
(3014576) Chloride [Moles/volume] in Serum or Plasma
7
22
4.41
2.13
7.4
11.4
mmol/l
106.3
105.0
—
7
22
(3021447) Carbon dioxide [Partial pressure] in Venous blood
7
22
4.41
2.13
5.7
11.0
kpa
5.5
5.6
—
7
22
(3000991) Gas panel - Venous blood
6
17
4.64
2.02
9.2
3.5
—
—
—
0
0
(3024354) Oxygen [Partial pressure] in Venous blood
6
21
3.68
1.66
6.0
11.2
kpa
5.8
4.2
—
6
21
(3014111) Lactate [Moles/volume] in Serum or Plasma
5
20
3.01
1.23
6.2
10.8
mmol/l
1.2
1.5
—
5
20
(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma
11
68
2.46
1.09
15.9
8.3
mmol/l
1.2
1.2
1.23
11
63
(3015377) Calcium [Moles/volume] in Serum or Plasma
8
44
2.40
1.03
5.1
2.5
mmol/l
2.3
2.3
—
8
37
(3033658) Prothrombin time (PT) actual/Normal
6
30
2.45
0.97
4.5
9.9
%
90.7
86.4
—
6
30
(3003694) ABO and Rh group [Type] in Blood
7
41
2.11
0.81
1.1
1.9
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
8
48
2.14
0.77
2.1
3.0
—
—
—
0
0
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
5
29
1.98
0.69
2.6
1.6
—
—
—
0
0
(3009508) Creatinine [Moles/volume] in Urine
6
36
1.97
0.64
6.0
2.6
mmol/l
7.3
8.1
—
6
29
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
0
23
0.00
0.62
0.0
1.3
—
—
—
0
0
(40758558) Short blood count panel - Blood
7
44
1.93
0.59
12.6
6.5
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
10
75
1.70
0.48
4.0
4.9
—
—
—
0
0
(46235355) HIV 1 and 2 tests - Meaningful Use set
5
31
1.83
0.48
3.2
1.9
—
—
—
0
0
(3044889) 12 lead EKG panel
12
94
1.75
0.47
5.8
3.3
—
—
—
0
0
(3007164) IgA [Mass/volume] in Serum or Plasma
5
32
1.76
0.47
1.6
1.5
g/l
1.0
3.0
—
5
22
(3012516) Albumin [Mass/volume] in Urine
5
32
1.76
0.47
7.0
2.9
mg/l
7.3
1811.1
—
5
23
(3011397) Hemoglobin [Presence] in Urine by Test strip
5
33
1.69
0.45
5.2
3.5
—
—
—
0
0
(3020682) Albumin/Creatinine [Ratio] in Urine
5
33
1.69
0.45
8.6
3.9
mg/mmol
1.4
5.0
—
5
21
(3041096) Erythrocytes [Presence] in Urine by Automated
5
34
1.63
0.44
10.4
3.8
—
—
—
0
0
(40760892) CBC W Ordered Manual Differential panel - Blood
5
35
1.58
0.43
7.8
11.4
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
0
18
0.00
0.42
0.0
1.2
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
6
41
1.67
0.41
4.3
4.0
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
6
45
1.48
0.38
15.0
3.3
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
7
54
1.47
0.36
10.0
3.9
—
—
—
0
0
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
14
121
1.59
0.34
25.8
12.4
ml/min/173m2
81.8
85.7
0.18
14
97
(3037467) Urinalysis macro (dipstick) panel - Urine
8
100
0.66
0.33
15.1
4.1
—
—
—
0
0
(3021960) Folate [Moles/volume] in Serum or Plasma
5
39
1.38
0.25
2.8
1.3
nmol/l
30.4
22.8
—
5
34
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
5
40
1.34
0.25
4.0
2.1
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
11
0.00
0.22
0.0
1.6
—
—
—
0
0
(43054914) Glucose tolerance 2 hours panel - Serum or Plasma
0
11
0.00
0.22
0.0
3.1
—
—
—
0
0
(4010399)
0
10
0.00
0.22
0.0
1.5
—
—
—
0
0
(3015736) pH of Urine
7
58
1.33
0.22
10.1
3.6
—
—
—
0
0
(3003338) MCHC [Mass/volume]
12
131
0.77
0.21
39.8
21.6
g/l
330.1
332.3
0.40
12
131
(3000492) Spirometry study
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
6
51
1.26
0.10
1.3
2.3
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
6
53
1.19
0.10
3.8
3.0
—
—
—
0
0
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3034770) Mitochondria Ab [Titer] in Serum
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(1002224) Polysomnography panel
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016251) Hemoglobin.gastrointestinal [Presence] in Stool
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
(3041008) Bicarbonate [Moles/volume] standard in Arterial cord blood
0
5
0.00
0.00
0.0
1.0
—
17.6
—
0
5
(3005033) Fetal Nuchal fold Thickness US
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3000764) Benzodiazepines [Presence] in Urine
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3050129) First trimester maternal screen panel - Serum or Plasma
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
5
52
0.95
0.00
8.6
12.3
—
—
—
0
0
(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
(3043238) Trisomy 21 risk [Likelihood] in Fetus
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
(3023410) Appearance of Cerebral spinal fluid
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3008757) Leukocyte morphology finding [Identifier] in Blood
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3047352) Trisomy 18 risk [Likelihood] in Fetus
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3011288) Drugs identified in Urine by Screen method
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(21494755) Public health laboratory ask at order entry panel
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3006598) pH of Arterial cord blood
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3003181) Sodium [Moles/volume] in Urine
0
5
0.00
0.00
0.0
2.2
—
67.6
—
0
5
(40768443) Skin Pathology biopsy report
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3044290) Cell count panel - Cerebral spinal fluid
0
5
0.00
0.00
0.0
10.8
—
—
—
0
0
(3003932) Carbon dioxide [Partial pressure] in Arterial cord blood
0
5
0.00
0.00
0.0
1.0
—
7.2
—
0
5
(3027944) Amphetamines [Presence] in Urine
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(42870560) Thyrotropin [Units/volume] in Cord blood
0
8
0.00
0.00
0.0
1.0
—
5.3
—
0
8
(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
(3013139) Helicobacter pylori Ag [Presence] in Stool
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3019473) Protein [Mass/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
6.7
—
233.8
—
0
6
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
10
98
1.04
0.00
3.9
3.6
—
—
—
0
0
(3004959) Base excess in Arterial cord blood by calculation
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021706) Oxygen [Partial pressure] in Arterial cord blood
0
5
0.00
0.00
0.0
1.0
—
3.5
—
0
5
(3043109) Cytology report of Tissue fine needle aspirate Cyto stain
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(4034850)
0
8
0.00
0.00
0.0
6.8
—
—
—
0
0
(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint Q17_ANOPH_MICROPHT_MACROP and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have Q17_ANOPH_MICROPHT_MACROP.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

Index endpoint: Q17_ANOPH_MICROPHT_MACROP – Nanophthalmos, microphthalmos and macrophthalmos

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data